<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>122-CHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>122-CHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
<ATC code="A02BA51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slowing of the elimination of the chloroquine and risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>122-CHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
